Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Emergent Biosolutions (EBS)
NYSE:EBS
EBS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.48 - $15.10
Previous CloseN/A
Volume320.20K
Average Volume (3M)929.66K
Market Cap
$526.67M
Enterprise Value$983.86M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.46
Next Earnings
Feb 20, 2025EPS Estimate
-0.43Last Dividend Ex-Date
Aug 01, 2016Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding54,184,185
10 Day Avg. Volume813,879
30 Day Avg. Volume929,663
Standard Deviation0.36
R-Squared0.06
Alpha-0.00486
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.48
Price to Cash Flow (P/CF)0.90
P/FCF Ratio0.90
Enterprise Value/Market Cap1.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda41.51
Forecast
1Y Price Target
$15.00Price Target Upside54.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Emergent Biosolutions News
---
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceThe analyst reiterates a Buy rating for Emergent BioSolutions, reflecting confidence in the company's strategic initiatives and potential growth.
Government ContractsA contract modification for the second option period was exercised for Emergent BioSolutions' Zaire Ebola virus vaccine, valued at approximately $16.7M, indicating continued government support and investment.
Strategic InitiativesEmergent BioSolutions entered into a six-year agreement to obtain exclusive North American commercial rights to KLOXXADO, a higher dosage naloxone agent, which is expected to enhance efforts in combating high-potency opioid overdoses.
Bears Say
Dependency On Government ContractsPotential for Emergent BioSolutions to generate additional favorable news flow from more contract awards from the U.S. and international governments for its MCM products.
Infectious Disease ChallengesContinued tailwinds from the Mpox epidemic and possibly other infectious diseases for which Emergent can provide solutions.
Market CompetitionNARCAN continues to maintain market share due to brand recognition and the transition to the OTC channel.
---
Ownership Overview
2.49% Insiders
11.57% Mutual Funds
11.08% Other Institutional Investors
55.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EBS FAQ
What was Emergent Biosolutions’s price range in the past 12 months?
Emergent Biosolutions lowest stock price was $1.48 and its highest was $15.10 in the past 12 months.
What is Emergent Biosolutions’s market cap?
Emergent Biosolutions’s market cap is $526.67M.
When is Emergent Biosolutions’s upcoming earnings report date?
Emergent Biosolutions’s upcoming earnings report date is Feb 20, 2025 which is in 3 days.
How were Emergent Biosolutions’s earnings last quarter?
Emergent Biosolutions released its earnings results on Nov 06, 2024. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $0.103 by $1.267.
Is Emergent Biosolutions overvalued?
According to Wall Street analysts Emergent Biosolutions’s price is currently Undervalued.
Does Emergent Biosolutions pay dividends?
Emergent Biosolutions pays a Notavailable dividend of $1.855 which represents an annual dividend yield of N/A. See more information on Emergent Biosolutions dividends here
What is Emergent Biosolutions’s EPS estimate?
Emergent Biosolutions’s EPS estimate is -0.43.
How many shares outstanding does Emergent Biosolutions have?
Emergent Biosolutions has 54,184,185 shares outstanding.
What happened to Emergent Biosolutions’s price movement after its last earnings report?
Emergent Biosolutions reported an EPS of $1.37 in its last earnings report, beating expectations of $0.103. Following the earnings report the stock price went up 19.565%.
Which hedge fund is a major shareholder of Emergent Biosolutions?
Currently, no hedge funds are holding shares in EBS
---
Emergent Biosolutions Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (54.32% Upside)
$15.00 (54.32% Upside)
Blogger Sentiment
Bullish
EBS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 21.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $272.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
475.14%
12-Months-Change
Fundamentals
Return on Equity
-34.64%
Trailing 12-Months
Asset Growth
-21.94%
Trailing 12-Months
Company Description
Emergent Biosolutions
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
---
EBS Company Deck
---
EBS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as the completion of the stabilization phase, improved financial performance, debt reduction, and increased product sales. However, some challenges remain, particularly in maintaining competitive pricing for NARCAN and managing revenue timing for medical countermeasures. Overall, the positive developments seem to outweigh the challenges.Read More>---
EBS Stock 12 Month Forecast
Average Price Target
$15.00
▲(54.32% Upside)
Technical Analysis
Best Analysts Covering EBS
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-7.84%
initiated a buy rating 6 months ago
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -7.84% per trade.
---